590 related articles for article (PubMed ID: 30657254)
1. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
2. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
[TBL] [Abstract][Full Text] [Related]
3. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW
Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991
[TBL] [Abstract][Full Text] [Related]
4. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
5. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
6. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
7. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
[TBL] [Abstract][Full Text] [Related]
8. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.
Zhang K; Chen J; Zhou H; Chen Y; Zhi Y; Zhang B; Chen L; Chu X; Wang R; Zhang C
Cell Death Dis; 2018 Feb; 9(3):312. PubMed ID: 29472524
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
10. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
[TBL] [Abstract][Full Text] [Related]
11. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
13. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
[TBL] [Abstract][Full Text] [Related]
14. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
15. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
16. RNA m
Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
[TBL] [Abstract][Full Text] [Related]
17. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
18. N
Xu J; Wan Z; Tang M; Lin Z; Jiang S; Ji L; Gorshkov K; Mao Q; Xia S; Cen D; Zheng J; Liang X; Cai X
Mol Cancer; 2020 Nov; 19(1):163. PubMed ID: 33222692
[TBL] [Abstract][Full Text] [Related]
19. Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
Sun T; Liu H; Ming L
Cell Physiol Biochem; 2017; 44(2):716-727. PubMed ID: 29169150
[TBL] [Abstract][Full Text] [Related]
20. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
